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Safety and Immunogenicity of a New Trivalent Inactivated  
Split-virus Influenza Vaccine in Healthy Korean Children:  
A Randomized, Double-blinded, Active-controlled, Phase III Study
We report results of a randomized, double-blinded, active-controlled, phase III study 
conducted to evaluate the immunogenicity and safety of a new trivalent inactivated split-
virus influenza vaccine (GC501) manufactured by the Green Cross Corporation in Korea. A 
total of 283 healthy children aged 6 months to  < 18 yr were randomized to receive either 
GC501 or control. Of the GC501 recipients, seroconversion occurred in 48.5% for A/H1N1, 
67.7% for A/H3N2 and 52% for influenza B. The proportion of subjects who had post-
vaccination hemagglutination-inhibition titers of 1:40 or greater was 90.7% for A/H1N1, 
86.8% for A/H3N2 and 82.4% for influenza B in the GC501 recipients. No serious adverse 
events related to vaccination, or withdrawals because of adverse events were reported. The 
majority of solicited adverse events were mild in intensity. GC501 vaccine has good 
tolerability and favorable immunogenicity in children aged 6 months to  < 18 yr. The 
addition of one more brand of influenza vaccine may allow for better global accessibility of 
vaccine for epidemics or future pandemics.
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INTRODUCTION
Because children have a high infection rate during community 
outbreaks of influenza and have an important role in transmis-
sion of influenza (1, 2), sufficient vaccination coverage among 
children can reduce age-specific and population-level illness 
attack rates (3). In Korea, annual influenza immunization for all 
children 6 months through 59 months of age and children who 
are at increased risk of severe complications from influenza vi-
ral infection is included in the national immunization program. 
Influenza immunization for healthy children  ≥ 60 months of 
age is recommended as an optional vaccine by the Korean Pe-
diatric Society and the decision for administration can be made 
by their parents or physicians.
  The influenza vaccine use in Korea has increased and the num-
ber of doses distributed/1,000 total population each year in 2003 Kang J-H, et al.  •  Trivalent Inactivated Influenza Vaccine in Children
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reached the highest level in the world (4). However, all influenza 
vaccines were imported from manufacturers located in vaccine-
producing countries. Recently Green Cross Corporation (Yon-
gin, Republic of Korea) completed the influenza vaccine plant 
in Hwasun, Jeonnam Province, Korea. The first domestically de-
veloped, seasonal, trivalent inactivated influenza vaccine was 
available for clinical trial in 2008, and  a clinical trial has been 
performed to examine the immunogenicity and safety of this 
influenza vaccine in healthy children and adolescents. There 
has been no publication on clinical trial of seasonal influenza 
vaccine in Korean children. It has been reported that this vac-
cine was well tolerated and induced robust immune response 
in both young adults and the elderly (5). 
 
MATERIALS AND METHODS
Study design
The purpose of this study was to evaluate the immunogenicity 
and safety of a new trivalent inactivated split-virus influenza vac-
cine (GC501, Green Cross Corporation) in healthy children from 
6 months to  < 18 yr of age. This study was conducted as a phase 
III, randomized, double-blinded, active-controlled, multi-cen-
ter trial at nine sites in Seoul, Gyeonggi and Gyeongnam prov-
ince, the Republic of Korea. Subjects who met the entry criteria 
for the study were randomized in a 4:1 ratio to receive either a 
Green Cross influenza vaccine or active control (Fluarix
®, Glaxo-
SmithKline Biologicals, Rixensart, Belgium). Because this study 
was not designed as an active control non-inferiority trial, the 
active control was not chosen to compare immunogenicity. The 
active control was used to provide information for vaccine de-
velopment and production strategies in the future. The study sub-
jects received different doses of the vaccine according to their 
ages. The subjects from 6 months to  < 3 yr of age received 0.25 
mL dose of vaccine and the subjects from 3 to  < 18 yr of age re-
ceived 0.5 mL dose of vaccine. 
  Subjects younger than 9 yr of age who had not been previous-
ly immunized against influenza received 2 doses of vaccine with 
one injection at day 0 and the other at day 28 (6). The vaccine 
was administered by intramuscular injection.
Vaccines 
The study vaccine is a purified, split-virus vaccine with each dose 
containing 15 μg each of the three contemporary influenza hem-
agglutinin antigens per 0.5 mL dose (total 45 μg). The vaccine 
was composed of the 2008-2009 Northern Hemisphere recom-
mended formulation: A/Brisbane/59/2007 IVR-148(H1N1), A/
Uruguay/716/2007 NYMC X-175C (H3N2), and B/Florida/4/ 
2006. The vaccine was prepared in embryonated chicken eggs 
with standard techniques. The control vaccine (Fluarix
®) was a 
0.5 mL commercial trivalent, inactivated split vaccine (Fluarix
®) 
in pre-filled syringes containing 15 μg of each of the three con-
temporary influenza hemagglutinin antigens. The control vac-
cine contained A/Brisbane/59/2007 IVR-148 (H1N1), A/Uru-
guay/716/2007 NYMC X-175C (H3N2), and B/Brisbane/3/2007.
Subjects
Healthy children from 6 months to  < 18 yr of age were eligible 
for enrollment. Exclusion criteria included hypersensitivity to 
any component of the vaccines (including eggs); immunosup-
pressive disorder; receipt of immunosuppressive or immuno-
modulating agents; history of Guillain-Barré syndrome; Down 
syndrome or cytogenetic disorder; any coagulation disorder con-
traindicating intramuscular injection; a current febrile illness or 
other acute illness; administration of gamma globulin during 
the previous 3 months; receipt of an influenza vaccine during 
the previous 6 months; and receipt of licensed inactivated or 
live vaccines within the preceding one month.
Safety assessment 
At the first visit, parents were given a digital thermometer and a 
diary card containing a list of solicited adverse events and their 
grades. On the day of immunization day subjects were observed 
at the study site for a period of 30 min after vaccination to detect 
any immediate adverse reactions. For the next 7 days subjects 
or their parents recorded, in the diary card, the severity of solic-
ited local and systemic adverse events, axillary temperature and 
concomitant medications taken. Subjects used a standard scale 
to grade adverse events (7).
  The solicited local adverse events included; pain, tenderness, 
redness and swelling. The solicited systemic adverse events were; 
fever, headache, malaise, shivering, fatigue, sweating, myalgia 
and arthralgia. The reports of other complaints were collected 
during the 28 days period after vaccination. Serious adverse 
events were reported within 24 hr. 
Immunogenicity assessment
Sampling for immunogenicity assays was performed pre-first 
dose (day 0) and 28 days after the last vaccination. Antibody re-
sponses were detected by means of hemagglutination-inhibi-
tion (HI) assays, according to established procedures and with 
use of chicken erythrocytes (8, 9), at the Korea University Guro 
Hospital. Titers of anti–hemagglutinin antibodies that were be-
low the detection limit (i.e., < 1:10) were assigned a value of 1:5, 
and titers above 1:5,120 were assigned a value of 1:5,120.
  The primary immunogenicity end points after vaccination 
were the proportion of subjects with seroconversion (a prevac-
cination titer of less than 1:10 with a post vaccination antibody 
titer of 1:40 or more or a prevaccination titer of 1:10 or more with 
a 4-fold or more increase in antibody titer) and the proportion 
of subjects with an antibody titer of 1:40 or more on hemagglu-
tination-inhibition assays (seroprotection rate). The secondary 
immunogenicity end points after vaccination were the geomet-Kang J-H, et al.  •  Trivalent Inactivated Influenza Vaccine in Children
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ric mean titer (GMT) and geometric mean titer ratio (i.e., the 
ratio of the geometric mean titer after vaccination to the geomet-
ric mean titer before vaccination, GMTR) and the proportion of 
subjects with a prevaccination titer of less than 1:40 with a 4-fold 
or more increase in antibody titer.
Statistical analysis 
The primary objectives of this study were to demonstrate that 
the lower boundary of the two-sided 95% confidence interval 
(CI) for the percent of subjects achieving seroconversion for HI 
antibody met or exceeded 40% and the lower boundary of the 
two-sided 95% CI for the percent of subjects achieving an HI an-
tibody titer  ≥ 1:40 met or exceeded 70% (10). 
  The sample size was chosen based on the power required to 
meet the immunogenicity endpoints. The true seroconversion 
rate was assumed to be at least 55%, so that with a total sample 
size of N = 155, the power for this comparison would exceed 
96.3% for each antigen. Assuming the true seroprotection rate 
was at least 85%, then with a total sample size of N = 85, the pow-
er for this comparison would exceed 96.3% for each antigen. A 
sample size of 222 subjects in study group was designed to ob-
tain at least 155 evaluable subjects, allowing an attrition rate up 
to 30%. A sample size of 58 subjects in the control group was de-
cided as 25% of study group, allowing an attrition rate up to 30%. 
  The immunological and safety endpoint analyses were de-
scriptive with calculation of two-sided 95% CI. For dichotomous 
variables, the 95% CI was calculated with the exact method for 
proportions. Geometric mean titers and 95% CI were calculated 
using the mean, and lower and upper limits of the 95% CI of log-
transformed titers. For categorical variables, statistical summa-
ries included counts and percentages relative to the group. All 
of the comparisons use the chi-square test or Fisher’s exact test 
for contingency tables and the t-test for continuous variables. 
The safety population included all subjects that received a dose 
of influenza vaccine. All tests were two-sided with a significant 
level of 0.05. Statistical analyses were performed using SPSS ver-
sion 12.0 (SPSS Inc., Chicago, IL, USA). 
Ethics statement
The study was conducted in accordance with the Declaration of 
Helsinki and the standards of Korean Good Clinical Practice by 
the Korea Food and Drug Administration. The protocol and con-
sent forms were approved by the institutional review board of 
each participating study site and Korea Food and Drug Admin-
istration (Biopharmaceutical Policy Division-No. 619). Informed 
written consent was obtained from all parents and/or partici-
pants following a detailed explanation of schedules and the con-
tents of the study.
RESULTS
Study subjects
From September 25 to November 12, 2008, 283 subjects were 
enrolled. One subject dropped out after consent but before the 
first vaccine dose. Overall, 282 subjects who received the GC501 
Table 1. Demographic characteristics of the subjects 
Characteristics  GC501 (n = 226)  Control (n = 56)
Age (yr)
   Mean ± SD
   Median
   Min-max
 
  6.8 ± 4.4
6.0
0.0, 17.0
 
  7.3 ± 4.0
7.0
0.0, 17.0
Sex-No. (%)
   Male
   Female
 
114 (50.4)
112 (49.6)
 
27 (48.2)
29 (51.8)
Body weight (kg)
   Mean ± SD
   Median
   Min-max
 
  28.8 ± 16.6
22.8
7.5, 80.0
 
  30.1 ± 16.7
26.3
8.0, 83.4
Height (cm)
   Mean ± SD
   Median
   Min-max
 
121.2 ± 27.4
120.0
57.0, 175.0
 
123.9 ± 25.5
125.8
60.0, 178.0
Dose-No. (%)
   One dose
   Two dose
 
206 (91.2)
20 (8.9)
 
55 (98.2)
1 (1.8)
Fig. 1. Enrollment and follow-up of 
the study subjects.Kang J-H, et al.  •  Trivalent Inactivated Influenza Vaccine in Children
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or control were included in the safety population (Table 1). A 
total of 255 subjects who received 1 or 2 doses of the GC501/con-
trol as their immunization status, and had a valid serology re-
sult were included in the immunogenicity population. Of the 
255 subjects, 253 completed the study protocol (Fig. 1). 
Immunogenicity
Table 2 presents the immunogenicity data on the GC501 and 
control vaccine groups by per protocol analysis. Seroconversion 
occurred in 48.5% for A/H1N1, 67.7% for A/H3N2 and 52% for 
B in the GC501 group. The lower boundary of the two-sided 95% 
CI for the seroconversion rate of each subtype exceeded 40%. For 
each strain, the proportion of subjects with a baseline HI titers 
of 1:40 or greater were similar for the GC501 and control vaccine 
groups. The proportion of subjects who had post-vaccination HI 
titers of 1:40 or greater was 90.7% for A/H1N1, 86.8% for A/H3N2 
and 82.4% for B in the GC501 group. The lower boundary of the 
two-sided 95% CI for the seroprotection rate of each subtype 
exceeded 70%. Between the GC501 and control vaccine groups, 
the seroconversion rates and the seroprotection rates were com-
parable for A/H1N1 and A/H3N2. But for B strain, the serocon-
version rates (P = 0.004) and the seroprotection rates (P = 0.014) 
were lower in the GC501 group than the control group. Geomet-
ric mean ratio was 5.6 for A/H1N1, 9.1 for A/H3N2, and 4.6 for 
B in the GC501 group.
  Table 3 presents the seroprotection rates of the GC501 and con-
trol vaccine groups according to age by intention to treat analy-
sis. Among subjects younger than 3 years of age in GC501 group, 
the proportion of subjects who achieved seroprotection was 75% 
(95% CI, 56.3-87.9) for the H1N1, 53.1% (95% CI, 35.0-70.5) for 
H3N2, and 40.6% (95% CI, 24.2-59.2) for B strain. The seropro-
tection rates were lower among subjects younger than 3 yr of 
age compared to those 3 yr of age or older in GC501 group.
Safety
Solicited local and systemic adverse events were reported with-
in seven days of vaccination and are shown in Table 4. Follow-
ing vaccination, the solicited local adverse events were reported 
by 142 (62.8%) out of 226 subjects, and the most common local 
adverse events was tenderness, which occurred in 119 (52.7%) 
subjects. The solicited systemic adverse events were reported by 
73 (32.3%) out of 226 subjects and the most commonly report-
ed solicited systemic adverse event was fatigue which occurred 
in 43 (19.0%) subjects. Fever was reported in 5 (3.1%) out of 226 
Table 2. Immunogenicity endpoint results
Influenza strains        Immunogenicity end point GC501 (n = 204) Control (n = 49)
H1N1 Seroconversion, % (95% CI)
Seroprotection Day 0, % (95% CI)
Seroprotection Day 28, % (95% CI)
GMR (95% CI)
GMT Day 0, (95% CI)
GMT Day 28, (95% CI)
48.5 (41.5-56.0)
56.9 (49.8-63.7)
90.7 (85.6-94.2)
5.6 (4.4-7.2)
39.5 (30.9-50.8)
222.5 (178.3-275.0)
59.2 (44.3-72.7)
55.1 (40.4-69.1)
93.9 (82.1-98.4)
8.2 (4.9-14.0)
35.5 (2.9-55.1)
291.9 (188.8-454.7)
H3N2 Seroconversion, % (95% CI)
Seroprotection Day 0, % (95% CI)
Seroprotection Day 28, % (95% CI)
GMR (95% CI)
GMT Day 0, (95% CI)
GMT Day 28, (95% CI)
67.7 (60.7-73.9)
48.0 (41.0-55.1)
86.8 (81.1-91.0)
9.1 (7.1-11.4)
29.8 (23.3-37.8)
269.5 (211.2-346.2)
63.3 (48.3-76.2)
49.0 (34.6-63.5)
89.8 (77.0-96.2)
9.3 (5.7-15.1)
29.3 (18.6-46.5)
272.0 (17.2-433.6)
B Seroconversion, % (95% CI)
Seroprotection Day 0, % (95% CI)
Seroprotection Day 28, % (95% CI)
GMR (95% CI)
GMT Day 0, (95% CI)
GMT Day 28, (95% CI)
47.6 (40.6-54.6)
52.0 (44.9-59.0)
82.4 (76.3-87.2)
4.6 (3.7-5.7)
30.2 (24.1-38.0)
140.1 (110.7-176.5)
71.4 (56.5-83.0)
59.2 (44.3-72.7)
95.9 (84.9-99.3)
8.6 (5.6-13.1)
30.8 (20.2-47.1)
264.4 (188.9-372.0)
Seroconversion was defined as a prevaccination antibody titer of 1:10 or less and a postvaccination titer of 1:40 or more. Seroprotection was defined as a postvaccination anti-
body titer of 1:40 or more. CI, confidence interval; GMR, geometric mean of post- to pre-vaccination titer ratios; GMT, geometric mean titer. 
Table 3. Percentage of subjects with seroprotective levels of antibodies by influenza strain and age group
Influenza strains
6 mo - < 3 yr 3 - < 9 yr 9 - < 18 yr
GC501 (n = 32) Control (n = 5) GC501 (n = 104) Control (n = 24) GC501 (n = 69) Control (n = 21)
H1N1 day 0   9.4 (2.5, 26.2) 0 61.5 (51.5, 70.8) 62.5 (40.8, 80.5) 71.0 (58.7, 81.0) 57.1 (34.4, 77.4)
H1N1 day 28   75.0 (56.3, 87.9)   80.0 (29.9, 99.0) 92.3 (85.0, 96.4) 91.7 (71.5, 98.5) 95.7 (87.0, 98.9) 100
H3N2 day 0 12.5 (4.1, 29.9) 20.0 (1.1, 70.1) 63.5 (53.4, 72.5) 62.5 (40.8, 80.5) 40.6 (29.1, 53.1) 42.8 (22.6, 65.6)
H3N2 day 28   53.1 (35.0, 70.5)   80.0 (29.9, 99.0) 93.3 (86.2, 97.0) 100 92.8 (83.2, 97.3) 81.0 (57.4, 93.7)
B day 0 6.25 (1.1, 22.2) 0 53.8 (43.8, 63.6) 54.2 (33.2, 73.8) 69.6 (57.2, 79.8) 81.0 (57.4, 93.7)
B day 28   40.6 (24.2, 59.2)     80 (29.9, 99.0) 87.5 (79.2, 92.9) 100 92.8 (83.2, 97.3) 95.2 (74.1, 99.8)
Data are presented % (95% confidence interval). Seroprotective level was defined as an antibody titer of 1:40 or more. mo, months; yr, years.Kang J-H, et al.  •  Trivalent Inactivated Influenza Vaccine in Children
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subjects and 2 of these had fever  > 38.5°C. The majority of so-
licited adverse events were mild in intensity.
  Unsolicited adverse events were reported by 53 (23.5%) out of 
226 subjects during the study period. The most common events 
were respiratory related disorders (n = 33, 14.6%). No serious 
adverse events related to vaccination, or withdrawals because 
of adverse events were reported.
 
DISCUSSION
Immunization against influenza is considered to be a key pub-
lic-health intervention to control both seasonal epidemics and 
pandemic influenza. In 2006, Global Action Plan (GAP) was de-
veloped by WHO for increasing the supply of influenza pandem-
ic vaccines in order to reduce the anticipated gap between po-
tential vaccine demand and supply during an influenza pan-
demic. They identified three main approaches: an increase in 
seasonal vaccine use; an increase in production capacity; and 
further research and development. Major progress in the devel-
opment of new production capacity has been achieved by WHO 
support to the manufacturers of 11 developing countries. One of 
them is Green Cross Corporation in the Republic of Korea (11). 
  This study evaluated the safety and the immunogenicity of the 
first Korean influenza vaccine in healthy children. This influen-
za vaccine appeared to be safe and well tolerated. The adverse 
events were generally mild and consistent with previous reports 
for inactivated influenza vaccine in children (12, 13). 
  The FDA provides recommendations for clinical data to sup-
port license approvals for new seasonal inactivated influenza 
vaccines (10). The recommendations have been modified from 
guidelines by “Committee for Medicinal Products for Human 
Use of the European Medicines Agency” (14). For the pediatric 
population, the requirements are that the lower boundary of the 
two-sided 95% CI for the percent of subjects achieving serocon-
version for HI antibody should meet or exceed 40% and the lower 
boundary of the two-sided 95% CI for the percent of subjects 
achieving an HI antibody titer  ≥ 1:40 should meet or exceed 
70%. Overall, the GC501 vaccine met the criteria. Previous stud-
ies reported that split-virus influenza vaccines were shown to be 
immunogenic for healthy children (15). The immunogenicity 
data of this study were consistent with previous reports that were 
included healthy children (15-17). However, subjects younger 
than 3 yr of age in GC501 group had lower antibody response to 
vaccine, especially for H3N2 and B antigens. In terms of the an-
tibody responses to influenza B antigens after vaccination, the 
responses can be lower than responses to influenza A antigen 
in young children (13, 18). The numbers of subject younger than 
3 yr of age were only 32 and 5 in the GC501 group and control 
group, respectively. The result suggest that studies evaluating 
efficacy of the GC501 vaccine or non-inferiority immunogenic-
ity trials of HI antibody responses to the GC501 vaccine as com-
pared to a licensed seasonal inactivated influenza vaccine are 
needed in young children. 
  The limitations of this study include the following. First, al-
though it had active control group, the control group was not 
chosen to compare to the immunogenicity of GC501 group and 
the size of control group was small. Therefore, there was no use-
ful information from the active control. Second, the study design 
was not stratified for the various age groups. The results showed 
that immunogenicity of GC501 vaccine satisfied the criteria sug-
gested by FDA as a whole. However, immunogenicity among 
young children was not satisfactory, and the small number of 
Table 4. Solicited adverse events within 7 days after vaccination
Adverse events
GC501 (n = 226)  
% (95% CI)
Control (n = 56)  
% (95% CI)
Any ≥ Grade 2 Any ≥ Grade 2
Solicited local events
   Pain
   Tenderness
   Redness
   Swelling
  
  50.0 (43.3, 56.7)
  52.7 (45.9, 59.3)
  26.1 (20.6, 32.4)
11.5 (7.8, 16.6)
  
1.3 (0.3, 4.2)
2.2 (0.8, 5.4)
  7.1 (4.2, 11.5)
3.1 (1.4, 6.5)
  
   48.2 (34.8, 61.8)
   55.4 (41.6, 68.4)
   19.6 (10.7, 32.8)
 17.9 (9.3, 30.9)
  
             0 (NA)
1.8 (0.1, 10.8)
1.8 (0.1, 10.8)
1.8 (0.1, 10.8)
Solicited systemic events
   Fever
   Headache
   Malaise
   Shivering
   Fatigue
   Sweating
   Myalgia
   Arthralgia
  
  3.1 (1.4, 6.54)
  9.7 (6.3, 14.6)
  9.3 (6.0, 14.0)
5.8 (3.2, 9.9)
  19.0 (14.3, 24.9)
  6.2 (3.6, 10.4)
13.7 (9.7, 19.1)
3.1 (1.4, 6.5)
  
1.3 (0.3, 4.2)
1.8 (0.6, 4.8)
0.9 (0.2, 3.5)
0.9 (0.2, 3.5)
1.3 (0.3, 4.2)
0.9 (0.2, 3.5)
2.7 (1.1, 6.0)
              0 (NA)
  
               0 (NA)
 10.7 (4.4, 22.6)
   1.8 (0.1, 10.8)
   8.9 (3.3, 20.4)
   8.9 (3.3, 20.4)
               0 (NA)
 17.9 (9.3, 30.9)
   3.6 (0.6, 13.4)
  
             0 (NA)
1.8 (0.1, 10.8)
             0 (NA)
             0 (NA)
             0 (NA)
             0 (NA)
1.8 (0.1, 10.8)
             0 (NA)
Pain was grade 0 (absent), grade 1 (does not interfere with activity), grade 2 (repeated use of non-narcotic pain reliever  > 24 hr or interferes with activity), grade 3 (any use of 
narcotic pain reliever or prevents daily activity), or grade 4 (emergency room visit or hospitalization). Tenderness was grade 0 (absent), grade 1 (mild discomfort to touch), grade 
2 (discomfort with movement), grade 3 (significant discomfort at rest), or grade 4 (emergency room visit or hospitalization). Fever was grade 0 ( < 38.0°C), grade 1 (38.0-38.4°C), 
grade 2 (38.5-38.9°C), grade 3 (39.0-40.0°C), or grade 4 ( > 40.0°C). Other adverse events were grade 1 (does not interfere with activity), grade 2 (interferes with activity), 
grade 3 (prevents daily activity), or grade 4 (emergency room visit or hospitalization). CI, confidence interval; NA, not applicable.Kang J-H, et al.  •  Trivalent Inactivated Influenza Vaccine in Children
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subjects in this age group precludes any conclusion. Because 
the recommended doses and amounts of vaccine were differ-
ent according to age, lack of stratification of age was the limita-
tion of this study.
  The results of this study indicate that GC501 vaccine has good 
tolerability and favorable immunogenicity in children aged 6 
months to  < 18 yr. An addition of one more brand of influenza 
vaccine might give better global accessibility of vaccine to epi-
demics or future pandemics.
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Safety and Immunogenicity of a New Trivalent Inactivated Split-virus Influenza 
Vaccine in Healthy Korean Children: A Randomized, Double-blinded,  
Active-controlled, Phase III Study
Jin-Han Kang, Chi-Eun Oh, Jina Lee, Soo-Young Lee, Sung-Ho Cha, Dong Soo Kim, Hyun-Hee Kim, Jung-Hyun Lee, Jin-Tack Kim,  
Sang-Hyuk Ma, Young-Jin Hong, Hee Jin Cheong and Hoan-Jong Lee
We evaluated the immunogenicity and safety of a new trivalent inactivated split-virus influenza vaccine (GC501) manufactured by 
the Green Cross Corporation in Korea. A total of 283 healthy children were randomized to receive either GC501 or control. Overall, 
the GC501 vaccine met both FDA and EMEA criteria. No serious adverse events related to vaccination were reported. GC501 
vaccine has good tolerability and favorable immunogenicity. The addition of one more brand of influenza vaccine may allow for 
better global accessibility and affordability of vaccine for epidemics or future pandemics.